← Product Code [JKA](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JKA) · K991843 # GREINER MINICOLLECT LITHIUM HEPARIN GEL BLOOD COLLECTION TUBE (K991843) _Greiner Meditech, Inc. · JKA · Jun 25, 1999 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JKA/K991843 ## Device Facts - **Applicant:** Greiner Meditech, Inc. - **Product Code:** [JKA](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JKA.md) - **Decision Date:** Jun 25, 1999 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1675 - **Device Class:** Class 2 - **Review Panel:** Clinical Chemistry ## Indications for Use To collect, transport, separate and process capillary blood for testing plasma in the clinical laboratory. ## Device Story The Greiner MiniCollect® is a non-sterile, non-evacuated capillary blood collection tube. It contains lithium heparin anticoagulant and an inert acrylic separation gel. The device is used by healthcare professionals to collect capillary blood samples. The tube features a rubber cap with 'cross-cuts,' allowing for direct collection and sampling without cap removal. After collection, the tube facilitates the separation of plasma from cellular components via the gel barrier. The device is used in clinical laboratory environments to prepare samples for subsequent diagnostic testing. It provides a closed-system approach to capillary blood handling, reducing exposure risks and simplifying laboratory workflows. ## Clinical Evidence Bench testing only. Performance was evaluated by comparing paired samples collected in the Greiner MiniCollect® and the predicate Becton Dickinson Microtainer® tubes. Testing included 22 analytes and 4 hormones, demonstrating good correlation between the two devices. ## Technological Characteristics Non-sterile, non-evacuated capillary blood collection tube. Materials: polypropylene plastic tube, rubber cap with cross-cuts, lithium heparin anticoagulant, inert acrylic separation gel. Mechanical separation principle via gel barrier. Standalone device. ## Regulatory Identification A blood specimen collection device is a device intended for medical purposes to collect and to handle blood specimens and to separate serum from nonserum (cellular) components prior to further testing. This generic type device may include blood collection tubes, vials, systems, serum separators, blood collection trays, or vacuum sample tubes. ## Predicate Devices - Becton Dickinson Microtainer® Brand heparin tubes with gel separator ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ ## I. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS Greiner Meditech. Inc. (., Greiner") is submitting a 510(k) pre-market notification for its Greiner MiniCollect® Lithium Heparin Gel tube with Lithium Heparin and separation gel for capillary blood collection. The Greiner MiniCollect® is a non-sterile, non-evacuated blood collection device containing lithium heparin anticoagulant and an inert acrylic barrier material, intended to collect, transport, separate and process capillary blood for testing serum. Greiner is claiming substantial equivalence to Becton Dickinson's Microtainer® Brand heparin tubes with gel separator. Both blood collection tubes have the same intended use and are made out of the same material, polypropylene plastic. The Greiner MiniCollect® cap is made from rubber and has "cross-cuts" to allow for direct collection into and sampling from the tube without having to remove the cap. Becton Dickinson's Microtainer® Brand tube caps are polypropylene stoppers. The equivalency of assay results for both tubes was evaluated by testing paired samples collected in Greiner MiniCollect® Lithium Heparin Gel tubes and Becton Dickinson Microtainer Brand tubes with lithium heparin and gel separator. Test results from paired samples for 22 analytes and 4 hormones were evaluated demonstrating good correlation. Greiner's 510(k) has been submitted on May 28,1999 by Doug Harris, Managing Director, Greiner Meditech, Inc., 260 Gateway Drive, Suite 17A, Bel Air, MD 21014 (410/836-8228). {1}------------------------------------------------ Image /page/1/Picture/1 description: The image is a black and white seal for the Department of Health & Human Services. The seal is circular and contains an image of an eagle with its wings spread. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are written around the edge of the circle. The eagle is facing to the right. 이 이 지원 이상 이상 이상 이 대한민국 대학교 대학교 문학 역사 1992년 1992년 1992년 1992년 1992년 1992년 1992년 1992년 1992년 1992년 1992년 19 이후 기자 : 1 Food and Drug Administration 2098 Gaither Road Rockville MD 20850 # JUN 25 1999 Mr. Douglas L. Harris Managing Director Greiner Meditech, Inc. 260 Gateway Drive Suite 17A Bel Air, Maryland 21014 Re: K991843 > Trade Name: MiniCollect® Lithium Heparin Gel Blood Collection Tube Regulatory Class: II Product Code: JKA Dated: May 28, 1999 Received: May 28, 1999 ### Dear Mr. Harris: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {2}------------------------------------------------ #### Page 2 Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Sutman Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ # STATEMENT OF INDICATIONS FOR USE 510(k) Number (if known): K991843 Device Name: MiniCollect® Lithium Heparin Gel Blood Collection Tube Indications for Use: To collect, transport, separate and process capillary blood for testing plasma in the clinical laboratory. Jean Cooper (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number K 99 18 43 Prescription Use *X* Over-The-Counter Use _ --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JKA/K991843](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JKA/K991843) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com